Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 10/20 | 0.55 |
| ▸ | FABP3 | P05413 | 1/20 | 0.43 |
| ▸ | FABP4 | P15090 | 1/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.43 |
| ▸ | PHLPP2 | Q6ZVD8 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SRC | P12931 | 1/20 | 0.42 |
| ▸ | DHODH | Q02127 | 1/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.42 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4490345 | 0.84 | FABP3 (0.51) | FABP3FABP4MAPTSMN1; SMN2HPGD | |
| SCHEMBL5207437 | 0.81 | MEN1 (0.64) | PHLPP2MAPTSMN1; SMN2HPGDMEN1 | |
| SCHEMBL4482947 | 0.79 | AKR1C3 (0.58) | MAPTSMN1; SMN2HPGDMEN1LMNA | |
| SCHEMBL5202876 | 0.79 | AKR1C3 (0.62) | MAPTSMN1; SMN2HPGDMEN1LMNA | |
| SCHEMBL4472958 | 0.79 | SMN1; SMN2 (0.50) | PHLPP2MAPTSMN1; SMN2HPGDMEN1 | |
| SCHEMBL5202789 | 0.79 | AKR1C3 (0.60) | PHLPP2MAPTSMN1; SMN2HPGDMEN1 | |
| Hydrochloric Acid SCHEMBL11240701 | 0.79 | LCK (0.52) | LCKCHRNA7HPGDKDM4EALDH1A1 | |
| SCHEMBL5207302 | 0.78 | MEN1 (0.50) | PHLPP2MAPTHPGDMEN1LMNA | |
| SCHEMBL4496284 | 0.77 | KDM4E (0.53) | FABP3FABP4MAPTSMN1; SMN2HPGD | |
| SCHEMBL4492706 | 0.77 | CSNK1D (0.47) | FABP3FABP4MAPTSMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7482455-B2 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-01-27 | — | — | US | claimed |
| EP-1556379-A4 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2007-06-13 | — | — | EP | claimed |
| US-20060106058-A1 | Chemical compounds | BURGESS JOELLE L | 2006-05-18 | — | — | US | claimed |
| EP-1556379-A2 | CHEMICAL COMPOUNDS | SmithKline Beecham Corporation (US) | 2005-07-27 | — | — | EP | claimed |
| WO-2004034985-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-04-29 | — | — | WO | claimed |
| US-7482455-B2 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-01-27 | — | — | US | disclosed |
| EP-1490044-A4 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORP (US) | 2008-04-16 | — | — | EP | disclosed |
| EP-1556379-A4 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2007-06-13 | — | — | EP | disclosed |
| US-20060106058-A1 | Chemical compounds | BURGESS JOELLE L | 2006-05-18 | — | — | US | disclosed |
| EP-1556379-A2 | CHEMICAL COMPOUNDS | SmithKline Beecham Corporation (US) | 2005-07-27 | — | — | EP | disclosed |
| EP-1490044-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2004-12-29 | — | — | EP | disclosed |
| WO-2004034985-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-04-29 | — | — | WO | disclosed |
| WO-2003084524-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2003-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106058-A1 | Chemical compounds | YARS1, DAPK3, NEK3 | LCK 802/4885FABP3 3871/4885FABP4 4681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.